Your browser doesn't support javascript.
loading
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs, Charles S; Shitara, Kohei; Di Bartolomeo, Maria; Lonardi, Sara; Al-Batran, Salah-Eddin; Van Cutsem, Eric; Ilson, David H; Alsina, Maria; Chau, Ian; Lacy, Jill; Ducreux, Michel; Mendez, Guillermo Ariel; Alavez, Alejandro Molina; Takahari, Daisuke; Mansoor, Wasat; Enzinger, Peter C; Gorbounova, Vera; Wainberg, Zev A; Hegewisch-Becker, Susanna; Ferry, David; Lin, Ji; Carlesi, Roberto; Das, Mayukh; Shah, Manish A.
Afiliação
  • Fuchs CS; Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT, USA. Electronic address: charles.fuchs@yale.edu.
  • Shitara K; National Cancer Center Hospital East, Kashiwa, Japan.
  • Di Bartolomeo M; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Lonardi S; Istituto Oncologico Veneto-IRCCS, Padova, Italy.
  • Al-Batran SE; Institute of Clinical Cancer Research at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany.
  • Van Cutsem E; University Hospitals Gasthuisberg, Leuven and KULeuven, Belgium.
  • Ilson DH; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alsina M; Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
  • Chau I; Royal Marsden Hospital, Sutton, Surrey, United Kingdom.
  • Lacy J; Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT, USA.
  • Ducreux M; Gustave Roussy Cancer Centre, Grand Paris, Villejuif, France; Université Paris-Saclay, France.
  • Mendez GA; Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina.
  • Alavez AM; Center for Clinical Care and Research in Oncology, Merida, Yucatan, Mexico.
  • Takahari D; The Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • Mansoor W; The Christie NHS Foundation Trust, Manchester, UK.
  • Enzinger PC; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gorbounova V; N N Blokhin Russian Cancer Research Center, Moscow, Russia.
  • Wainberg ZA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Hegewisch-Becker S; HOPE-Practice for Oncology, Hamburg, Germany.
  • Ferry D; Eli Lilly and Company, New York City, NY, USA.
  • Lin J; Eli Lilly and Company, Indianapolis, IN, USA.
  • Carlesi R; Eli Lilly Italia, Florence, Italy.
  • Das M; Eli Lilly and Company, Indianapolis, IN, USA.
  • Shah MA; Weill Cornell Medical College, NY, USA; New York Presbyterian Hospital, New York, NY, USA.
Lancet Oncol ; 20(3): 420-435, 2019 03.
Article em En | MEDLINE | ID: mdl-30718072
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Cisplatino / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Cisplatino / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article